Copenhagen, Denmark
Copenhagen, Denmark

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsvaerd, Denmark, with production facilities in seven countries, and affiliates or offices in 75 countries.Novo Nordisk manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.Novo Nordisk employs more than 40,000 people globally, and marketed its products in 180 countries. It is the largest publicly traded company in the Nordic countries by market capitalization. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt.Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations .The company was ranked 25th among 100 best companies to work for in 2010 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth. Novo Nordisk was ranked 72nd on “Fortune’s 100 Best Companies to Work For®” list within the U.S. state of New Jersey as of January 2014. Wikipedia.


Time filter

Source Type

Patent
Novo Nordisk AS | Date: 2017-01-19

The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.


Patent
Novo Nordisk AS | Date: 2017-03-08

Drug delivery device adapted to receive a cartridge, comprising a drive tube with an inner thread, a motor assembly comprising a drive shaft and being adapted to be received inside the drive tube, a drive member attached to the drive shaft and with an outer thread in engagement with the drive tube inner thread. The drive tube is arranged axially displaceable but non-rotational relative to the motor assembly, whereby rotation of the drive member results in axial, non-rotational displacement of the drive tube. To provide flexibility the drive shaft is connected to the drive member via a first flexible joint, and the motor assembly proximal portion is connected to a support structure via a second flexible joint.


Patent
Novo Nordisk AS | Date: 2017-03-15

The present invention relates to use of a GLP-1 agonist and an anti-IL-2 antibody in treatment and/or prevention of type 1 diabetes.


Patent
Novo Nordisk AS | Date: 2017-02-15

The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first Lys residue at a position corresponding to position 36 of GLP-1(7-37) (SEQ ID NO:1), a second Lys residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO : 1), and a maximum of seven amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 1); which derivative comprises two protractors attached to said first and second Lys residue, respectively, each via a linker; wherein the protractor is selected from : Chem. 1: HOOC-C6H4-0-(CH2)y-CO-*, and Chem. 2: HOOC-(CH2)x-CO-*, wherein y is an integer in the range of 8-11, and x is 12; and the linker comprises at least one of: Chem. 3: *-NH-CH(COOH)-(CH2)2-CO-*, Chem. 4: *-NH-CH((CH2)2-COOH)-CO-*, and/or Chem. 5: *-NH-(CH2)2-[0-(CH2)2]k-0-[CH2]n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical uses thereof, such as for the treatment of diabetes and obesity, as well as to the GLP-1 peptides forming part of these derivatives which have Lys residues at positions 36 and 37 and no other Lys residues, and the GLP-1(9-37) fragments thereof. The invention furthermore relates to an intermediate product comprising 3-carboxyphenoxy-nonanoic acid with a protection group at the carboxy group of the nonanoic acid, optionally via a linker. The derivatives have a very good potency and a long half-life which makes them potentially useful for, e.g., oral administration.


Patent
Novo Nordisk AS | Date: 2017-01-06

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.


Disclosed is a medical injection device (1) comprising a needle assembly (20) having a cannula (21) and a telescopic shield (30) for covering the distal tip (23) in a no use situation. The telescopic shield further carries a cleaning reservoir (40) for cleaning the needle cannula between two subsequent injections. The cleaning reservoir is provided with an opening (43) connecting to an overflow reservoir (51/55) such that the cleaning liquid contained in the cleaning reservoir can retract and expand upon temperature changes and does not enter the needle lumen instead.. In one example, the overflow reservoir is formed as a channel (51).


Patent
Novo Nordisk AS | Date: 2017-01-27

The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.


Patent
Novo Nordisk AS | Date: 2017-01-12

The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC(CH_(2)))_(x)CO*, and Chem. 16: HOOCC_(6)H_(4)O(CH_(2))_(y)CO*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *NHCH(CH_(2)OH)CO*. A preferred linker is gGlu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases.


Patent
Novo Nordisk AS | Date: 2017-03-08

A drug delivery device comprising drug expelling means for expelling an amount of drug, a number of user-oriented structures, and individual visual communication means arranged in the vicinity of at least two user-oriented structures. The device further comprises control means adapted to detect an error condition associated with each of the at least two structures, and actuate the visual communication means associated with a structure for which an error condition has been detected.


Patent
Novo Nordisk AS | Date: 2017-03-08

A protein purification process with virus inactivation or removal uses caprylic acid (octanoic acid) at acidic pH. The method comprises caprylic acid treatment as part of the chromatographic step so as to perform viral inactivation without a discontinuous process and without the requirement of attention by personnel, particularly when the pH adjustment of the eluate is performed automatically by eluting into buffer. The method of the invention further results in mycoplasmas being inactivated, and reduced impurities like Host Cell Protein (HCP).

Loading Novo Nordisk AS collaborators
Loading Novo Nordisk AS collaborators